New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Baptist GallwitzDept Medicine IV, T&uuml;bingen University, Otfried-M&uuml;ller-Str, 10, 72076 T&uuml;bingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once dail...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Baptist Gallwitz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/7c898e859a724600b3976e93c46cb673
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7c898e859a724600b3976e93c46cb673
record_format	dspace
spelling	oai:doaj.org-article:7c898e859a724600b3976e93c46cb6732021-12-02T07:25:20ZNew treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin1178-7007https://doaj.org/article/7c898e859a724600b3976e93c46cb6732010-05-01T00:00:00Zhttp://www.dovepress.com/new-treatments-in-the-management-of-type-2-diabetes-a-critical-apprais-a4384https://doaj.org/toc/1178-7007Baptist GallwitzDept Medicine IV, T&uuml;bingen University, Otfried-M&uuml;ller-Str, 10, 72076 T&uuml;bingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin Baptist GallwitzDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 117-124 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Baptist Gallwitz New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
description	Baptist GallwitzDept Medicine IV, T&uuml;bingen University, Otfried-M&uuml;ller-Str, 10, 72076 T&uuml;bingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin
format	article
author	Baptist Gallwitz
author_facet	Baptist Gallwitz
author_sort	Baptist Gallwitz
title	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_short	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_full	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_fullStr	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_full_unstemmed	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
title_sort	new treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/7c898e859a724600b3976e93c46cb673
work_keys_str_mv	AT baptistgallwitz newtreatmentsinthemanagementoftype2diabetesacriticalappraisalofsaxagliptin
_version_	1718399410556108800

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Ejemplares similares